---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-089912"
form_type: "8-K"
ticker: "EMMA"
cik: "0000822370"
company_name: "Emmaus Life Sciences, Inc."
filed_at: "2026-08-14T19:11:19+00:00"
generated_at: "2026-08-14T19:12:37.348471+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Emmaus Q2 2026 net income $1.3M vs $1.1M loss; revenue up 124% on NIT license

## Summary
- Net revenues $6.3M for Q2 2026 vs $2.8M in Q2 2025, driven by NIT license revenue recognition.
- Operating expenses fell to $2.1M from $3.0M; income from operations $3.8M vs $0.4M loss.
- Net income $1.3M ($0.02 EPS) vs net loss $1.1M (-$0.02 EPS); cash $2.8M at June 30, 2026.
- NIT exclusive license for Endari in US/Canada effective May 15, 2026; upfront payment and royalties recognized.
- Weighted-average shares 70.2M vs 63.9M in prior-year quarter.

## SEC filing metadata
- accession: 0001213900-26-089912
- form_type: 8-K
- ticker: EMMA
- cik: 0000822370
- company_name: Emmaus Life Sciences, Inc.
- filed_at: 2026-08-14T19:11:19+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/822370/000121390026089912/0001213900-26-089912-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/822370/000121390026089912/ea0302099-8k_emmaus.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-089912
- JSON: https://secwatch.observer/filing/0001213900-26-089912.json
- Plain text: https://secwatch.observer/filing/0001213900-26-089912.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.